Peterson Amy C. 4
4 · CytomX Therapeutics, Inc. · Filed Jul 21, 2022
Insider Transaction Report
Form 4
Peterson Amy C.
EVP, Chief Development Officer
Transactions
- Sale
Common Stock
2022-07-20$1.42/sh−7,463$10,612→ 62,690 total - Award
Common Stock
2022-07-19+20,000→ 70,153 total
Footnotes (4)
- [F1]Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
- [F2]Includes 40,000 restricted stock units.
- [F3]Reflects the adjusted total which includes the purchase of 3,732 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022.
- [F4]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.